Observational Registry of Effectiveness and Safety of Tenecteplase in Real World Settings in China-ORIENTAL
The ORIENTAL study is a prospective, multicenter, continuously enrolled real-world cohort designed to evaluate the effectiveness and safety of intravenous tenecteplase for acute ischemic stroke (AIS) in routine clinical practice across China. Approximately 10,000 patients from about 200 hospitals will be included. Eligible adults with imaging-confirmed AIS who receive tenecteplase as part of standard care will be consecutively enrolled and followed through 90 days. The study will describe patient characteristics, treatment processes, functional outcomes, and safety events, and will also explore inter-hospital variability and subgroup differences to support quality improvement and guide nationwide implementation of tenecteplase therapy.
• Adults aged 18 years or older;
• Diagnosed with acute ischemic stroke confirmed by imaging (CT or MRI);
• Treated with intravenous tenecteplase at the participating institution;
• Provided written informed consent, signed by the patient or their legally authorized representative;
• Capable of completing follow-up assessments.